Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. (Q38200419)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Tong-Ming Fu

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Zhiqiang An

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

28 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

2525-2533

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Management of cytomegalovirus infection in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Priorities for CMV vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Genetic content of wild-type human cytomegalovirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

High-resolution human cytomegalovirus transcriptome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Coding potential of laboratory and clinical strains of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Decoding human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus reinfections in healthy seroimmune women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Desirability and feasibility of a vaccine against cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Maternal immunity and prevention of congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Correlates of protection induced by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Progress toward an elusive goal: current status of cytomegalovirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Clinical Trials of Immunization with the Towne 125 Strain of Human Cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

The attenuated Towne strain of human cytomegalovirus may revert to both endothelial cell tropism and leuko- (neutrophil- and monocyte-) tropism in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus vaccine virus (Towne strain) does not induce latency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Bacterial artificial chromosome clones of viruses comprising the towne cytomegalovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Vaccine prevention of maternal cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Crystal structure of glycoprotein B from herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Receptors and immune sensors: the complex entry path of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus genes in the 15-kilobase region are required for viral replication in implanted human tissues in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Humanized mice for immune system investigation: progress, promise and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Asymptomatic primary cytomegalovirus infection: virologic and immunologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Endothelial cells in human cytomegalovirus infection: one host cell out of many or a crucial target for virus spread?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Endothelial cells and CMV dissemination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Neutralizing activity of saliva against cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus viruria and DNAemia in healthy seropositive women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus strain diversity in seropositive women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Enzyme-linked immunosorbent assay method for detection of cytomegalovirus strain-specific antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Molecular epidemiology of primary human cytomegalovirus infection in pregnant women and their families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Rapid intrahost evolution of human cytomegalovirus is shaped by demography and positive selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Screening for cytomegalovirus during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy--a case-control study of the outcome in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Lymphoproliferative response in primary human cytomegalovirus (HCMV) infection is delayed in HCMV transmitter mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

Clinical and Laboratory Studies of Live Cytomegalovirus Vaccine Ad-169

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

inferred from DOI database lookup

7 January 2021

based on heuristic

Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

inferred from DOI database lookup

7 January 2021

based on heuristic

Detection of cytomegalovirus antibody by enzyme immunoassay and lack of evidence for an effect resulting from strain heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.057

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2014.03.057

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24681264%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference